Crohn's Disease (Regional Enteritis) of the Large Intestine and Its Distinction from Ulcerative Colitis by H
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Clinical Cases of Crohn's Disease in Pediatric Hirschprung's Patients
Open Access Austin Journal of Gastroenterology Case Report Clinical Cases of Crohn‘s Disease in Pediatric Hirschprung‘s Patients Cerniauskaite R1, Statkuviene J2, Labanauskas L2, Urbonas V3, Bagdzevicius S4, Adamonis K5, Abstract Rokaite R2, Janciauskas D6 and Kucinskiene R2* Crohn’s and Hirschsprung’s diseases are two different conditions of 1Department of Radiology, Vilnius University Hospital intestinal tract though both of them are genetically predisposed. Each disease Santariskiu Clinics, Lithuania have genetic mutations in some genes, however there are no evidence that 2Department of Pediatric gastroenterology, Hospital of there are mutations common to both conditions. Lithuanian University of Health Sciences, Lithuania 3Department of Pediatric gastroenterology, Vilnius We present 3 clinical cases of patients who underwent surgery in infancy University Hospital Santariskiu Clinics, Lithuania for Hirschsprung’s disease. Later in early childhood all the patients developed 4Department of Pediatric surgery, Hospital of Lithuanian clinical symptoms of inflammatory bowel disease and Crohn’s disease was University of Health Sciences, Lithuania diagnosed. Both conditions were confirmed histologically. After introducing the 5Department of Gastroenterology, Hospital of Lithuanian treatment for Crohn’s disease positive effect was shown. These cases raise University of Health Sciences, Lithuania the hypothesis that the two conditions may have similarities in etiology and 6Department of Pathology, Hospital of Lithuanian pathogenesis and may -
Traveler's Diarrhea
Traveler’s Diarrhea JOHNNIE YATES, M.D., CIWEC Clinic Travel Medicine Center, Kathmandu, Nepal Acute diarrhea affects millions of persons who travel to developing countries each year. Food and water contaminated with fecal matter are the main sources of infection. Bacteria such as enterotoxigenic Escherichia coli, enteroaggregative E. coli, Campylobacter, Salmonella, and Shigella are common causes of traveler’s diarrhea. Parasites and viruses are less common etiologies. Travel destination is the most significant risk factor for traveler’s diarrhea. The efficacy of pretravel counseling and dietary precautions in reducing the incidence of diarrhea is unproven. Empiric treatment of traveler’s diarrhea with antibiotics and loperamide is effective and often limits symptoms to one day. Rifaximin, a recently approved antibiotic, can be used for the treatment of traveler’s diarrhea in regions where noninvasive E. coli is the predominant pathogen. In areas where invasive organisms such as Campylobacter and Shigella are common, fluoroquinolones remain the drug of choice. Azithromycin is recommended in areas with qui- nolone-resistant Campylobacter and for the treatment of children and pregnant women. (Am Fam Physician 2005;71:2095-100, 2107-8. Copyright© 2005 American Academy of Family Physicians.) ILLUSTRATION BY SCOTT BODELL ▲ Patient Information: cute diarrhea is the most com- mised and those with lowered gastric acidity A handout on traveler’s mon illness among travelers. Up (e.g., patients taking histamine H block- diarrhea, written by the 2 author of this article, is to 55 percent of persons who ers or proton pump inhibitors) are more provided on page 2107. travel from developed countries susceptible to traveler’s diarrhea. -
Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms
nutrients Review Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms Annamaria Altomare 1,2 , Claudia Di Rosa 2,*, Elena Imperia 2, Sara Emerenziani 1, Michele Cicala 1 and Michele Pier Luca Guarino 1 1 Gastroenterology Unit, Campus Bio-Medico University of Rome, Via Álvaro del Portillo 21, 00128 Rome, Italy; [email protected] (A.A.); [email protected] (S.E.); [email protected] (M.C.); [email protected] (M.P.L.G.) 2 Unit of Food Science and Human Nutrition, Campus Bio-Medico University of Rome, Via Álvaro del Portillo 21, 00128 Rome, Italy; [email protected] * Correspondence: [email protected] Abstract: Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder charac- terized by abdominal pain associated with defecation or a change in bowel habits. Gut microbiota, which acts as a real organ with well-defined functions, is in a mutualistic relationship with the host, harvesting additional energy and nutrients from the diet and protecting the host from pathogens; specific alterations in its composition seem to play a crucial role in IBS pathophysiology. It is well known that diet can significantly modulate the intestinal microbiota profile but it is less known how different nutritional approach effective in IBS patients, such as the low-FODMAP diet, could be Citation: Altomare, A.; Di Rosa, C.; responsible of intestinal microbiota changes, thus influencing the presence of gastrointestinal (GI) Imperia, E.; Emerenziani, S.; Cicala, symptoms. The aim of this review was to explore the effects of different nutritional protocols (e.g., M.; Guarino, M.P.L. -
Mastocytic Enterocolitis
Patient Counseling Report MASTOCYTIC ENTEROCOLITIS WHAT IS MASTOCYTIC ENTEROCOLITIS? Mastocytic enterocolitis is a disease of the colon, or large intestine that is caused by an increased number of mast cells in the lining of the colon. It is believed that this increased number of mast cells is caused by a form of immune response by the gastrointestinal tract. This allergic response then causes a physical response by the body which results in diarrhea and abdominal pain. Previously, Mastocytic Enterocolitis was classifed as diarrhea-predominant irritable bowel syndrome (IBS) due to the fact that there was not a more specific diagnosis. With this diagnosis, a more specific treatment regimen can be offered with the hope of relieving symptoms. Mastocytic Enterocolitis affects patients as young as 16 and has been documented in patients as old as 85. Mastocytic Enterocolitis is not associated with an increased risk for cancer and patients diagnosed with this disease usually have a normal endoscopy and normal endoscopic findings. HOW IS MASTOCYTIC ENTEROCOLITIS DIAGNOSED? The goal of treatment is to try and reduce the number of mast cells During your endoscopy procedure, tissue biopsies were taken and sent to in the colon and relieve symptoms like abdominal pain, diarrhea, a specialized gastrointestinal pathology laboratory. At the laboratory, and weight loss. Most individuals respond well to treatment and see a special stain was utilized to highlight the mast cells in your tissue. a relatively dramatic reduction in their symptoms. Unfortunately, The special stain revealed that the number of mast cells in your tissue was treatment may not always work for patients and you and your doctor abnormally high and therefore you were diagnosed with Mastocytic may need to find another treatment regimen that can be successful for Enterocolitis. -
The Entire Intestinal Tract Surveillance Using Capsule Endoscopy After Immune Checkpoint Inhibitor Administration: a Prospective Observational Study
diagnostics Article The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study Keitaro Shimozaki 1 , Kenro Hirata 1,* , Sara Horie 1, Akihiko Chida 1, Kai Tsugaru 1, Yukie Hayashi 1, Kenta Kawasaki 1, Ryoichi Miyanaga 1, Hideyuki Hayashi 2 , Ryuichi Mizuno 3, Takeru Funakoshi 4, Naoki Hosoe 5, Yasuo Hamamoto 2 and Takanori Kanai 1 1 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan; [email protected] (K.S.); [email protected] (S.H.); [email protected] (A.C.); [email protected] (K.T.); [email protected] (Y.H.); [email protected] (K.K.); [email protected] (R.M.); [email protected] (T.K.) 2 Keio Cancer Center, Keio University School of Medicine, Tokyo 160-8582, Japan; [email protected] (H.H.); [email protected] (Y.H.) 3 Department of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan; [email protected] 4 Department of Dermatology, Keio University School of Medicine, Tokyo 160-8582, Japan; [email protected] 5 Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo 160-8582, Japan; [email protected] * Correspondence: [email protected]; Tel.: +81-3-3353-1211 Citation: Shimozaki, K.; Hirata, K.; Abstract: Background: Despite the proven efficacy of immune checkpoint inhibitors (ICIs) against Horie, S.; Chida, A.; Tsugaru, K.; various types of malignancies, they have been found to induce immune-related adverse events, such Hayashi, Y.; Kawasaki, K.; Miyanaga, as enterocolitis; however, the clinical features of ICI-induced enterocolitis remain to be sufficiently R.; Hayashi, H.; Mizuno, R.; et al. -
Resveratrol Alleviates Acute Campylobacter Jejuni Induced Enterocolitis in a Preclinical Murine Intervention Study
microorganisms Article Resveratrol Alleviates Acute Campylobacter jejuni Induced Enterocolitis in a Preclinical Murine Intervention Study Markus M. Heimesaat 1,* , Soraya Mousavi 1, Ulrike Escher 1,Fábia Daniela Lobo de Sá 2 , Elisa Peh 3 , Jörg-Dieter Schulzke 2 , Sophie Kittler 3, Roland Bücker 2 and Stefan Bereswill 1 1 Institute of Microbiology, Infectious Diseases and Immunology, Charité—University Medicine Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 12203 Berlin, Germany; [email protected] (S.M.); [email protected] (U.E.); [email protected] (S.B.) 2 Institute of Clinical Physiology, Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 12203 Berlin, Germany; [email protected] (F.D.L.d.S.); [email protected] (J.-D.S.); [email protected] (R.B.) 3 Institute for Food Quality and Food Safety, University of Veterinary Medicine Hannover, Foundation, 30559 Hannover, Germany; [email protected] (E.P.); [email protected] (S.K.) * Correspondence: [email protected]; Tel.: +49-30-450524318 Received: 7 October 2020; Accepted: 23 November 2020; Published: 25 November 2020 Abstract: The polyphenolic compound resveratrol has been shown to exert health-beneficial properties. Given globally emerging Campylobacter infections in humans, we addressed potential anti-pathogenic, immuno-modulatory and intestinal epithelial barrier preserving properties of synthetic resveratrol in the present preclinical intervention study applying a murine acute campylobacteriosis model. / Two days following peroral C. jejuni infection, secondary abiotic IL-10− − mice were either subjected to resveratrol or placebo via the drinking water. -
Reflux Esophagitis
Reflux Esophagitis KEY FACTS TERMINOLOGY • Caustic esophagitis • Inflammation of esophageal mucosa due to PATHOLOGY gastroesophageal (GE) reflux • Lower esophageal sphincter: Decreased tone leads to IMAGING increased reflux • Irregular ulcerated mucosa of distal esophagus • Hydrochloric acid and pepsin: Synergistic effect • Foreshortening of esophagus: Due to muscle spasm CLINICAL ISSUES • Inflammatory esophagogastric polyps: Smooth, ovoid • 15-20% of Americans commonly have heartburn due to elevations reflux; ~ 30% fail to respond to standard-dose medical • Hiatal hernia in > 95% of patients with stricture therapy ○ Probably is result, not cause, of reflux ○ Prevalence of GE reflux disease has increased sharply • Peptic stricture (1- to 4-cm length): Concentric, smooth, with obesity epidemic tapered narrowing of distal esophagus • Symptoms: Heartburn, regurgitation, angina-like pain TOP DIFFERENTIAL DIAGNOSES ○ Dysphagia, odynophagia • Scleroderma • Confirmatory testing: Manometric/ambulatory pH- monitoring techniques • Drug-induced esophagitis ○ Endoscopy, biopsy • Infectious esophagitis Imaging in Gastrointestinal Disorders: Diagnoses • Eosinophilic esophagitis (Left) Graphic shows a small type 1 (sliding) hiatal hernia ſt linked with foreshortening of the esophagus, ulceration of the mucosa, and a tapered stricture of distal esophagus. (Right) Spot film from an esophagram shows a small hiatal hernia with gastric folds ſt extending above the diaphragm. The esophagus appears shortened, presumably due to spasm of its longitudinal muscles. A stricture is present at the gastroesophageal (GE) junction, and persistent collections of barium indicate mucosal ulceration. (Left) Prone film from an esophagram shows a tight stricture ſt just above the GE junction with upstream dilation of the esophagus. The herniated stomach is pulled taut as a result of the foreshortening of the esophagus, a common and important sign of reflux esophagitis. -
Pdf (30 November 2019, Date Last Accessed)
Gastroenterology Report, 8(1), 2020, 25–30 doi: 10.1093/gastro/goz065 Advance Access Publication Date: 17 December 2019 Review REVIEW Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy Eva Rajha1, Patrick Chaftari1,*, Mona Kamal1, Julian Maamari2, Christopher Chaftari3, Sai-Ching Jim Yeung1 1Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Schoool of Medicine, Lebanese American University, Byblos, Lebanon; 3Biomedical Engineering, College of Engineering, Texas A&M University, College Station, TX, USA *Corresponding author. Department of Emergency Medicine, Unit 1468, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Tel: þ1-832-833-1702; Email: [email protected] Abstract Immunotherapy with checkpoint inhibitors has revolutionized cancer therapy and is now the standard treatment for several different types of cancer, supported by favorable outcomes and good tolerance. However, it is linked to multiple immune manifestations, referred to as immune-related adverse events (irAEs). These adverse events frequently affect the skin, colon, endocrine glands, lungs, and liver. The gastrointestinal system is one of the most commonly affected organ sys- tems and is responsible for the most frequent emergency visits resulting from irAEs. However, because immune checkpoint inhibitors are a recent addition to our arsenal of cancer drugs, many health-care providers remain unfamiliar with the management of irAEs. Gastroenterologists involved in the treatment of oncology patients who have received checkpoint inhibitors are currently encountering cases of abdominal pain, diarrhea, and other nonspecific symptoms that may be challenging to manage. This article reviews the gastrointestinal, hepatic, and pancreatic toxicities of checkpoint inhibitors and provides an approach to their diagnosis and recommended workup. -
Eosinophilic Enteritis, a Rare Dissease
Case Report Adv Res Gastroentero Hepatol Volume 16 Issue 1 - October 2020 DOI: 10.19080/ARGH.2020.16.555930 Copyright © All rights are reserved by Andy Gabriel Rivera Flores Eosinophilic Enteritis, A Rare Dissease Andy Rivera*, Roberto Délano, Jose de Jesús Herrera Esquivel and Carlos Valenzuela Salazar Endoscopy Unit, Hospital General, Manuel Gea González, México Submission: October 10, 2020; Published: October 22, 2020 *Corresponding author: Andy Gabriel Rivera Flores, Endoscopy Unit, Hospital General, Dr Manuel Gea González, México City, México Abstract Eosinophilic enteritis is a rare disease characterized by eosinophilic infiltration in the small intestine; In the absence of non-gastrointestinal diseasesKeywords: that cause eosinophilia or causes known as parasites, medications, or malignancies. Eosinophilic enteritis; Endoscopy; Treatment Introduction Eosinophilic enteritis is a rare disease characterized by physical examination revealed slight dryness of the mucosa, the rest without abnormalities. The results of the laboratory tests were eosinophilic infiltration of the small intestine; In the absence of within normal parameters (hematic biometry, 35-element blood non-gastrointestinal diseases that cause eosinophilia [1]. It was chemistry, general urinalysis, thyroid profile). A Simple Complete described in 1937 by Kaijser. The pathophysiology of this entity Abdominal Computerized Axial Tomography was performed with is not well described. The symptoms are manifested according oral and intravenous contrast, which demonstrated thickening of to the affected small intestine layer, the mucosa being the most the proximal small intestine that does not occlude the intestinal common (25-100%) characterized by weight loss, anemia, intestinal obstruction; Subserosa presents with eosinophilic lumen. Panendoscopy is performed where duodenal ulcers are positive stool guaiac; The Muscular (13-70%) presents data of observed in the first and second portion of the duodenum (Figure 1), taking biopsies of the duodenum and the Sydney protocol. -
Peptic Ulceration in Crohn's Disease (Regional Gut: First Published As 10.1136/Gut.11.12.998 on 1 December 1970
Gut, 1970, 11, 998-1000 Peptic ulceration in Crohn's disease (regional Gut: first published as 10.1136/gut.11.12.998 on 1 December 1970. Downloaded from enteritis) J. F. FIELDING AND W. T. COOKE From the Nutritional and Intestinal Unit, The General Hospital, Birmingham 4 SUMMARY The incidence of peptic ulceration in a personal series of 300 patients with Crohn's disease was 8%. Resection of 60 or more centimetres of the small intestine was associated with significantly increased acid output, both basally and following pentagastrin stimulation. Only five (4 %) of the 124 patients who received steroid therapy developed peptic ulceration. It is suggested that resection of the distal small bowel may be a factor in the probable increase of peptic ulceration in Crohn's disease. Peptic ulceration was observed in 4% of 600 1944 and 1969 for a mean period of 11-7 years patients with Crohn's disease by van Patter, with a mean duration of the disorder of 13.7 Bargen, Dockerty, Feldman, Mayo, and Waugh years. Fifty-one of these patients had Crohn's http://gut.bmj.com/ in 1954. Cooke (1955) stated that 11 of 90 patients colitis. Diagnosis in this series was based on with Crohn's disease had radiological evidence of macroscopic or histological criteria in 273 peptic ulceration whilst Chapin, Scudamore, patients, on clinical and radiological data in 25 Bagenstoss, and Bargen (1956) noted duodenal patients, and on clinical data together with minor ulceration in five of 39 (12.8%) successive radiological features in two patients with colonic patients with the disease who came to necropsy. -
ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults
602 PRACTICE GUIDELINES nature publishing group CME ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults Mark S. Riddle , MD, DrPH1 , H e r b e r t L . D u P o n t , M D 2 and Bradley A. Connor , MD 3 Acute diarrheal infections are a common health problem globally and among both individuals in the United States and traveling to developing world countries. Multiple modalities including antibiotic and non-antibiotic therapies have been used to address these common infections. Information on treatment, prevention, diagnostics, and the consequences of acute diarrhea infection has emerged and helps to inform clinical management. In this ACG Clinical Guideline, the authors present an evidence-based approach to diagnosis, prevention, and treatment of acute diarrhea infection in both US-based and travel settings. Am J Gastroenterol 2016; 111:602–622; doi: 10.1038/ajg.2016.126; published online 12 April 2016 INTRODUCTION supplements previously published Infectious Disease Society of Acute diarrheal infection is a leading cause of outpatient visits, America (IDSA) ( 5 ), and World Gastroenterology Organiza- hospitalizations, and lost quality of life occurring in both domes- tion guidelines ( 6 ). Th is guideline is structured into fi ve sections tic settings and among those traveling abroad. Th e Centers for of clinical focus to include epidemiology and population health, Disease Control and Prevention has estimated 47.8 million cases diagnosis, treatment of acute disease, evaluation of persisting occurring annually in the United States, at an estimated cost symptoms, and prevention. To support the guideline development, upwards of US$150 million to the health-care economy ( 1,2 ). -
Coeliac Disease Under a Microscope Histological Diagnostic Features And
Computers in Biology and Medicine 104 (2019) 335–338 Contents lists available at ScienceDirect Computers in Biology and Medicine journal homepage: www.elsevier.com/locate/compbiomed Coeliac disease under a microscope: Histological diagnostic features and confounding factors T ∗ Giulia Gibiinoa, , Loris Lopetusoa, Riccardo Riccib, Antonio Gasbarrinia, Giovanni Cammarotaa a Internal Medicine and, Gastroenterology and Hepatic Diseases Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy b Institute of Pathology, IRCCS Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy ARTICLE INFO ABSTRACT Keywords: Coeliac disease (CD) and gluten-related disorders represent an important cornerstone of the daily practice of Gluten gastroenterologists, endoscopists and dedicated histopathologists. Despite the knowledge of clinical, serological Intraepithelial lymphocyte (IEL) and histological typical lesions, there are some conditions to consider for differential diagnosis. From the first Microscopic enteritis description of histology of CD, several studies were conducted to define similar findings suggestive for micro- Non-coeliac gluten-sensitivity scopic enteritis. Considering the establishment of early precursor lesions, the imbalance of gut microbiota is Gut microbiota another point still requiring a detailed definition. This review assesses the importance of a right overview in case of suspected gluten-related disorders and the several conditions mimicking